Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline with a $3.2 billion bid to acquire Morphic and its mid-stage oral integrin therapy MORF-057.
The high value attached by pharma companies to inflammation and immunology (I&I) programmes is on display once again, as AbbVie agrees a deal worth up to $1.7 billion for an inflammator
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.
Johnson & Johnson’s blockbuster immunology drug Stelara is facing its first approved biosimilar in Europe, which is due to launch after the drug loses EU patent protec
AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S
Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phas